They demonstrated a significant accumulation of the [64Cu]Cu-DOTA-anti-CTLA-4 mAb in the CT26 tumor, suggesting its potential as a non-invasive method to evaluate CTLA-4 expression [18]. This evidence concerns the gene CTLA4 and neoplasm.